R
Robert B. Livingston
Researcher at University of Washington
Publications - 210
Citations - 24328
Robert B. Livingston is an academic researcher from University of Washington. The author has contributed to research in topics: Breast cancer & Lung cancer. The author has an hindex of 63, co-authored 208 publications receiving 23512 citations. Previous affiliations of Robert B. Livingston include Seattle Cancer Care Alliance & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton,Robert B. Livingston,David H. Johnson,James R. Rigas,Michael R. Johnston,Charles Butts,Yvon Cormier,Glenwood D. Goss,Richard Inculet,Eric Vallières,Willard A Fry,Drew Bethune,Joseph Ayoub,Keyue Ding,Lesley Seymour,Barbara Graham,Ming-Sound Tsao,David R. Gandara,Kenneth A. Kesler,Todd L. Demmy,Frances A. Shepherd +20 more
TL;DR: Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Journal ArticleDOI
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Paul E. Goss,James N. Ingle,Silvana Martino,Nicholas J. Robert,Hyman B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,Lois E. Shepherd,Kathleen I. Pritchard,Robert B. Livingston,Nancy E. Davidson,Larry Norton,Edith A. Perez,Jeffrey S. Abrams,Patrick Therasse,Michael Palmer,Joseph L. Pater +17 more
TL;DR: As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.
Journal ArticleDOI
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron,Donald A. Berry,Constance Cirrincione,Clifford A. Hudis,Eric P. Winer,William J. Gradishar,Nancy E. Davidson,Silvana Martino,Robert B. Livingston,James N. Ingle,Edith A. Perez,John T. Carpenter,David D. Hurd,James F. Holland,Barbara L. Smith,Carolyn I. Sartor,Eleanor H. Leung,Jeffrey S. Abrams,Richard L. Schilsky,Hyman B. Muss,Larry Norton +20 more
TL;DR: Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time, and Sequential chemotherapy is as effective as concurrent chemotherapy.
Journal ArticleDOI
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
Andrew T. Turrisi,KyungMann Kim,Ronald Blum,William T. Sause,Robert B. Livingston,Ritsuko Komaki,Henry N. Wagner,Seena C. Aisner,David H. Johnson +8 more
TL;DR: Four cycles of cisplatin plus etoposide and a course of radiotherapy beginning with cycle 1 of the chemotherapy resulted in overall two- and five-year survival rates of 44 percent and 23 percent, a considerable improvement in survival rates over previous results.
Journal ArticleDOI
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
Karen Kelly,John Crowley,Paul A. Bunn,Cary A. Presant,Patra K. Grevstad,Carol M. Moinpour,Scott D. Ramsey,Antoinette J. Wozniak,Geoffrey R. Weiss,Dennis F. Moore,Valerie Israel,Robert B. Livingston,David R. Gandara +12 more
TL;DR: PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer, and overall costs on the PC arm were higher than on the VC arm because of drug costs.